Global market

  • Crohn's disease (CD) and ulcerative colitis (UC) evolve with alternate outbreaks and remissions of variable duration in both cases. Tumor necrosis factor α antagonists (anti-TNF) have advanced in the treatment of patients with inflammatory bowel disease (IBD), which has improved the patient's quality of life by reducing the number of surgeries and hospitalizations.
  • Despite these advances, about 30% of patients do not respond to initial treatment after the induction period, and 20% to 50% of patients should be optimized to respond to treatment.
  • The prognosis of the outcome of the treatment is of great value in shaping the therapeutic strategy for these patients.

Our proposal

  • The use of RAID-Response will allow to significantly increase the efficacy of the therapies per patients of Crohn’s disease and ulcerative colitis, increase their quality of life and reduce important associated costs.


  • A clinical study is currently being carried out together with Hospital Universitari Dr Josep Trueta, Hospital Bellvitge, Institut d'Assistència Sanitària and Hospital Germans Trias i Pujol. We expect to launch it on the market by 2021.
  • RAID-Response will be on the market for patients who have been diagnosed with Crohn’s disease or ulcerative colitis.

2019 InSiGHT Meeting

2019 InSiGHT Meeting

By goodgut.eu, On 20 de March de 2019

The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) and the New Zealand Society ...